In a strategic move that signals a broader shift toward embedded AI in clinical workflows, Veeva Systems and OpenEvidence have announced a long-term partnership to develop and commercialize Open Vista, a novel AI-driven platform designed to unify trial access, evidence dissemination, and therapeutic adoption.

Vertical AI to Disrupt Clinical Development

At its core, Open Vista is poised to act as an intelligent bridge across fragmented segments of the healthcare and life sciences ecosystem—connecting drug developers, treating physicians, and patients at scale. With Veeva’s infrastructure spanning early development through commercialization, and OpenEvidence’s position as the most-used evidence-based AI tool among U.S. physicians, the joint platform is strategically positioned to influence decisions from molecule to market.

The technology will ingest peer-reviewed medical literature, real-world treatment data, and sponsor trial protocols to:

  • Match patients to open clinical trials in real-time based on clinical context.
  • Surface gaps in care and research using aggregated physician queries to inform pipeline strategy.
  • Accelerate post-approval adoption by pushing evidence-based recommendations at the point of care.

Positioning at the Intersection of Medical Practice and Development Strategy

Over 40% of U.S. physicians already rely on OpenEvidence for clinical decision support, creating a rich stream of query-based signals that reflect real-world unmet needs and practice behaviors. Open Vista will translate this into structured insights for life sciences sponsors, enabling a reverse feedback loop where the clinic informs the clinic—linking frontline practice with upstream development and downstream commercialization.

For pharmaceutical and biotech companies, this could unlock:

  • Faster accrual via physician-driven trial awareness.
  • Evidence-aligned adoption strategies post-approval.
  • Earlier visibility into treatment behaviors and real-world deviation from protocol or label.

Operational and Regulatory Impact

The anticipated 2026 rollout of Open Vista will coincide with increasing industry scrutiny on both trial equity and real-world applicability of regulatory decisions. AI-native platforms like Open Vista offer sponsors a way to address both:

  • Reducing barriers to participation by bringing trials into clinical workflows.
  • Informing regulatory submissions with real-time clinical usage trends.
  • Supporting access and education around therapies beyond academic hubs.

Strategic Implications for Life Sciences

This alliance underscores a broader trend of vertical AI specialization—where general-purpose models are being repurposed with domain-specific data, UX, and regulatory frameworks. Open Vista may emerge as a pivotal tool not just for accelerating development timelines, but for aligning products with actual prescriber behavior in the field.

For CROs and sites, the system promises improved trial matching fidelity and referral efficiency. For sponsors, it opens a new frontier in evidence-based engagement, where medical affairs, commercial teams, and trial operations are coordinated through shared AI insights.

Source: https://www.veeva.com/resources/openevidence-and-veeva-announce-open-vista-partnership/

Website |  + posts

Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.